Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets -Sarcoma treatment in progress

Journal of Drug Targeting

Volumn 20, Issue 2, 2012, Pages 185-193

  Krukemeyer, Manfred Georg ^a   Krenn, Veit ^b   Jakobs, Martin ^b   Wagner, Wolfgang ^a  

^a Paracelsus Hospital   (Germany)

^b Institute of Histology   (Germany)

Author keywords

Anthracyclines; Biodistribution; Magnetic drug targeting; Neoadjuvant therapy; Reticuloendothelial system; Sarcoma

Indexed keywords

DEXTRAN MAGNETITE; MITOXANTRONE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TARGETING; EXTRACORPOREAL MAGNET; MAGNET; MAGNETIC DRUG TARGETING; MAGNETIC FIELD; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEXTRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; MAGNETITE NANOPARTICLES; MAGNETS; MITOXANTRONE; RATS; RATS, INBRED STRAINS; RHABDOMYOSARCOMA;

EID: 84855700528     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.622399     Document Type: Article

References (21)

1. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS. (2000). Locoregional cancer treatment with magnetic drug targeting. Cancer Res, 60, 6641-6648.
2. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F. (2003). Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target, 11, 139-149. (Pubitemid 37236327)
3. Alexiou C, Jurgons R, Schmid R, Erhardt W, Parak F, Bergemann C, Iro H. (2005). Magnetic Drug Targeting-a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies. HNO, 53, 618-622. (Pubitemid 41151554)
4. Alexiou C, Schmid RJ, Jurgons R, Kremer M, Wanner G, Bergemann C, Huenges E, Nawroth T, Arnold W, Parak FG. (2006a). Targeting cancer cells: Magnetic nanoparticles as drug carriers. Eur Biophys J, 35, 446-450.
5. Alexiou C, Jurgons R, Seliger C, Iro H. (2006). Medical applications of magnetic nanoparticles. J Nanosci Nanotechnol, 6, 2762-2768. (Pubitemid 44579944)
6. Bergemann C, Muller-Schulte D, Oster J, . et al. (1999). Magnetic ionexchange nano-and microparticles for medical, biochemical and molecular biological applications. J Magn Magn Mater, 194, 45-52.
7. Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54, 631-651. (Pubitemid 35247520)
8. Brockstein BE. (2004). Metastatic osteosarcoma: A curable advanced malignancy. J Clin Oncol, 22, 5017; author reply 5017-5017; author reply 5018.
9. Gupta AK, Gupta M. (2005). Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26, 3995-4021. (Pubitemid 40044762)
10. Hayden JB, Hoang BH. (2006). Osteosarcoma: Basic science and clinical implications. Orthop Clin North Am, 37, 1-7. (Pubitemid 41719081)
11. Kohler N, Sun C, Wang J, Zhang M. (2005). Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir, 21, 8858-8864. (Pubitemid 41396647)
12. Krukemeyer MG, Wagner W, Jakobs M, Krenn V. (2009). Tumor regression by means of magnetic drug targeting. Nanomedicine (Lond), 4, 875-882.
13. Lordick F. (2005). Neoadjuvant therapy of squamous cell esophageal cancer. What is "evidence based"? Chirurg, 76, 1025-1032 [German]. (Pubitemid 41639856)
14. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. (1996). Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer Res, 56, 4694-4701. (Pubitemid 26338072)
15. Lubbe AS, Alexiou C, Bergemann C. (2001). Clinical applications of magnetic drug targeting. J Surg Res, 95, 200-206. (Pubitemid 34953556)
16. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. (2003). Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res, 63, 3154-3161. (Pubitemid 36735867)
17. Michiels L, Merregaert J. (1993). Retroviruses and oncogenes associated with osteosarcomas. Cancer Treat Res, 62, 7-18.
18. Peiper M, Zornig C. (2002). Lymphangiosarcoma in chronic lymphedema of the lower extremities. Three patients with Stewart-Treves-Syndrome. Chir Prax, 60, 63-69. (Pubitemid 34678815)
19. Rao BN, Rodriguez-Galindo C. (2003). Intra-arterial cisplatin in osteosarcoma: Same question, different answer. Ann Surg Oncol, 10, 481-483. (Pubitemid 40486906)
20. Rudge S, Peterson C, Vessely C, Koda J, Stevens S, Catterall L. (2001). Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC). J Control Release, 74, 335-340. (Pubitemid 32727641)
21. Siewert JR, Lordick F, Ott K, Brucher BL, Rosenberg R. (2006). Therapeutic strategies in locoregional recurrence of gastrointestinal tumors. Chirurg, 77, 227-235 [German]. (Pubitemid 43425742)